Efficacy and safety analysis of granulocyte colony-stimulating factor after chimeric antigen receptor-modified T cell therapy for relapsed/refractory B cell acute lymphoblastic leukemia
10.3969/j.issn.1000-484X.2024.12.024
- VernacularTitle:复发/难治急性B淋巴细胞白血病行CAR-T细胞治疗后接受粒细胞集落刺激因子的疗效及安全性分析
- Author:
Xinping CAO
1
;
Meng ZHANG
;
Xiaomei ZHANG
;
Mingfeng ZHAO
Author Information
1. 天津医科大学第一中心临床学院,天津 300392
- Keywords:
B cell acute lymphoblastic leukemia;
Chimeric antigen receptor-modified T cell;
Granulocyte colony-stimulating factor
- From:
Chinese Journal of Immunology
2024;40(12):2604-2608
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To retrospectively analyze efficacy and safety of granulocyte colony-stimulating factor(G-CSF)in relapsed/refractory B cell acute lymphoblastic leukemia(R/R B-ALL)patients with neutropenia(NE)after receiving CAR-T cell therapy.Methods:From March 2017 to December 2022,99 patients with R/R B-ALL developed NE after receiving CAR-T cell therapy in Tianjin First Central Hospital were collected and divided into two groups according to using time of G-CSF.One was early G-CSF group(received G-CSF within 7 days,n=56),the other was control group(received G-CSF after 7 d,n=43),whose recovery of NE and occurrence of adverse reactions after G-CSF were compared.Results:Duration of NE in early G-CSF group was shorter than control group[4(2,5.7)vs 11(9,14),P<0.05],but there were no significant differences in the lowest absolute neutrophil count(ANC),degree of NE inhibition and incidence of infection(P=0.261,P=0.09,P=0.111).There was no significant difference between incidence and severity of cytokine release syndrome(CRS)between two groups,and CRS was controllable in all patients.Conclusion:Early application of G-CSF in R/R B-ALL patients after CAR-T cell therapy can shorten duration of NE,and has no significant effect on adverse reactions after CAR-T cells.
